yk11 Chemical Properties

Melting point:

134-137°C

Boiling point:

564.4±50.0 °C(Predicted)

Density 

1.22±0.1 g/cm3(Predicted)

storage temp. 

-20°C Freezer

solubility 

Chloroform (Slightly), Methanol (Slightly)

form 

Solid

color 

White to Pale Yellow

InChI

InChI=1S/C25H34O6/c1-23-11-9-18-17-8-6-16(26)13-15(17)5-7-19(18)20(23)10-12-25(23)21(14-22(27)28-3)30-24(2,29-4)31-25/h13-14,17-20H,5-12H2,1-4H3/b21-14+/t17-,18+,19+,20-,23-,24?,25+/m0/s1

InChIKey

KCQHQCDHFVGNMK-PQUNLUOYSA-N

SMILES

O1C(C([H])([H])[H])(OC([H])([H])[H])O/C(=C(\[H])/C(=O)OC([H])([H])[H])/[C@]21C([H])([H])C([H])([H])[C@@]1([H])[C@]3([H])C([H])([H])C([H])([H])C4=C([H])C(C([H])([H])C([H])([H])[C@]4([H])[C@@]3([H])C([H])([H])C([H])([H])[C@@]12C([H])([H])[H])=O

yk11 Usage And Synthesis

Description

YK11 was first studied by Japanese researcher Yuichiro Kanno in 2011. It was found to be a partial agonist of the androgen receptor (AR), genetically selective, leading researchers to believe the compound was a SARM. YK11 is an experimental drug candidate and an unapproved substance for use in humans.

Uses

YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM).It is a gene-selective partial agonist of the androgen receptor (AR) and does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR.

Mechanism of action

YK-11 is an androgen receptor partial agonist that activates androgen receptor transcriptional activity in HEK293 cells overexpressing androgen receptors when used at a concentration of 0.1 μM.1 It induces expression of the androgen receptor target genes FKBP51 and FGF18 in HEK293 cells when used at a concentration of 10 μM. YK-11 accelerates nuclear translocation of androgen receptors without inducing interaction between the androgen receptor N- and C-termini. In C2C12 cells, YK-11 (500 nM) increases expression of the myogenic regulatory factors MyoD, Myf5, and myogenin, as well as follistatin (Fst), and induces myogenic differentiation.

References

[1] Yuichiro Kanno, et al. Exp Cell Res. Differential DNA-binding and cofactor recruitment are possible determinants of the synthetic steroid YK11-dependent gene expression by androgen receptor in breast cancer MDA-MB 453 cells DOI:10.1016/j.yexcr.2022.113333
[2] Su Jin Lee, et al. Biochem Biophys Res Commun. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis DOI:10.1016/j.bbrc.2021.01.030
[3] Tomofumi Yatsu, et al. Biol Pharm Bull. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells DOI:10.1248/bpb.b17-00748
[4] Mario Thevis, et al. Mol Cell Endocrinol. Detection of SARMs in doping control analysis DOI:10.1016/j.mce.2017.01.040
[5] Yuichiro Kanno, et al. Biol Pharm Bull. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression DOI:10.1248/BPB.B13-00231

yk11(1370003-76-1)Related Product Information

• YK11
• YKL-5-124
• 2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE
• YKL 06-061
• YL 0919
• YK-3-237
• YK-4-279